Metformin effect on Pre-diabetics

Clinical trial of Assessment of Metformin efficacy in Pre-diabetics (CAMP study)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211118053095N1

Enrollment

Unknown

Registered

2021-11-29

Start date

2021-11-22

Completion date

Unknown

Last updated

2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes. Prediabetes

Interventions

Intervention 1: Intervention group: metformin 500. Intervention 2: Control group: Placebo.

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Inclusion criteria

Inclusion criteria: people with non-diabetic hyperglycemia (?.?=HbA?C<?.?) at high cardiovascular risk (at least ??-year CVD risk =??% according to Framingham risk scoring QRISK?).

Exclusion criteria

Exclusion criteria: Pregnancy History of cardiovascular diseases

Design outcomes

Primary

Measure	Time frame
Cardiovascular diseases. Timepoint: each two months follow-ups. Method of measurement: self report through phone calls.	—

Secondary

Measure	Time frame
Death. Timepoint: Each two months follow-ups. Method of measurement: report of family members through phone call, Then receive the death document image.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarshad Farzadfar

Tehran University of Medical Sciences

farzadfar3@yahoo.com0912485343

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026